



12-13-04

(Pw)

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

18

Application Number

10/702,681

Filing Date

November 5, 2003

First Named Inventor

Deborah A. RATHJEN

Art Unit

1644

Examiner Name

I. Ouspenski

Attorney Docket Number

273402602309

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	1. Form PTO-1449 (14 pages) 2. Return Receipt Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement, Supplemental (3 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Kimberly A. Bolin		
Date	December 9, 2004	Reg. No.	44,546


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336623495US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 9, 2004

Signature:




(Georgina Matos)



PATENT
Docket No. 273402602309
Client Reference: 501927

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV336623498US, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 9, 2004

Signature:  (Georgina Matos)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Deborah A. RATHJEN et al.

Serial No.: 10/702,681

Filing Date: November 5, 2003

For: TUMOUR NECROSIS FACTOR
BINDING LIGANDS

Examiner: I. Ouspenski

Group Art Unit: 1644

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the co-pending related U.S. Patent Application No. 10/265,451, filed October 3, 2002. The present application is a continuation of U.S. Patent Application No. 10/453,176, filed June 6, 2003, which is a continuation of U.S. Patent Application No. 10/359,934, filed February 7, 2003, which is a continuation of U.S. Patent Application No. 10/327,541, filed

December 20, 2002, which is a continuation of U.S. Patent Application No. 10/265,451, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). If the Examiner requires additional copies of the documents, Applicants will be happy to provide them upon request. The Examiner is requested to make these documents of record in the application.

This Supplemental Information Disclosure Statement is submitted:

- With the application; accordingly, no fee or separate requirements are required.
- Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of __ is enclosed.
 - A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of __ is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **273402602309**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 9, 2004

Respectfully submitted,

By:


Kimberly A. Bolin
Registration No. 44,546

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5740
Facsimile: (650) 494-0792

Form PTO-1449

O -
DEC 09 2004
PATENT & TRADEMARK OFFICE
SCTBSUPPLEMENTAL INFORMATION
DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273402602309

Application Number 10/702,681

Applicant

Deborah A. RATHJEN et al.

Filing Date November 5, 2003

Group Art Unit 1644

Mailing Date December 7, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	01/22/2004	2004/0014227	Frederick et al.			
	2.	05/13/2004	2004/0092721	Rathjen et al.			
	3.	05/23/1989	4,833,092	Geysen			
	4.	03/16/1993	5,194,392	Geysen			
	5.	07/23/1996	5,539,084	Geysen			
	6.	01/21/1997	5,595,915	Geysen			
	7.	02/16/1999	5,872,210	Medabalimi			
	8.	12/07/1999	5,998,577	Geysen			
	9.	03/19/2002	6,358,920	Blaschuk et al.			
	10.	05/27/2003	6,569,996	Blaschuk et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	11.	05/02/1985	EP 0 138 855	Europe			
	12.	09/13/1984	WO 84/03564	WIPO			
	13.	05/27/1993	WO 93/09872	WIPO			
	14.	05/25/2000	WO 00/29851	WIPO			
	15.	08/23/2001	WO 01/60769	WIPO			
	16.	04/18/2002	WO 02/31510	WIPO			
	17.	08/29/2002	WO 02/066984	WIPO			
	18.	02/06/2003	WO 03/010536	WIPO			
	19.	05/13/2004	WO 04/039962	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant	Deborah A. RATHJEN et al.
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	20.	Aaskov, J.G. et al. (1989). "Serologically Defined Linear Epitopes in the Envelope Protein of Dengue 2 (Jamaica Strain 1409)," <i>Arch. Virol.</i> 105(3-4):209-221.
	21.	Aggarwal, B.B. et al. (December 1985). "Characterization of Receptors For Human Tumour Necrosis Factor and Their Regulation by γ -Interferon," <i>Nature</i> 318:665-667.
	22.	Alexander, H. et al. (April 1992). "Altering the Antigenicity of Proteins," <i>Proc. Natl. Acad. Sci. USA</i> 89:3352-3356.
	23.	American Thoracic Society, Centers for Disease Control and Prevention (2000). "Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection," <i>Am J. Respir. Crit. Care Med.</i> 161:S221-S247.
	24.	Anonymous (January 1992). "Characterization of Antipeptide Antibodies," <i>Chiron Pinnacles</i> 2(1):1-12.
	25.	Anonymous (April 1992). "Quantitative Peptide Hormone Receptor Studies on Extensive Analog Sets," <i>Chiron Pinnacles</i> 2(2):1-12.
	26.	Anonymous (January 1993). "Using Antigen Competition to Identify Sequential (Linear) Epitopes," <i>Chiron Pinpoints</i> 3(2):1-4.
	27.	Anonymous (September 1993). "Mapping Antibody-Defined Linear Epitopes," <i>Chiron Pinpoints</i> pp. 1-8.
	28.	Anonymous (2004). "Antibodies can bind linear peptides that represent adjacent amino acids that form a part of the epitope, though real linear peptides that represent a complete epitope are rare." Quote from <i>Open Biosystems: Antibody Services</i> located at < http://www.openbiosystems.com/pepscanpeptidarrays.php > last visited on October 19, 2004, one page.
	29.	Anonymous (2004). "In fact, linear and simple discontinuous epitopes form a small portion of most epitopes. In most cases, the amino acids that make up epitopes are located on different strands of the protein. These epitopes, known as the discontinuous scattered type, are difficult to map. Strategies that are being used to map these produce useful data only when the structure and conformation of the protein is known." Quote from <i>Open Biosystems: Antibody Services</i> located at < http://www.openbiosystems.com/pepscanpeptidarrays.php > last visited on October 19, 2004, one page.
	30.	Atassi, M.Z. (November 15, 1984). "Antigenic Structures of Proteins: Their Determination Has Revealed Important Aspects of Immune Recognition and Generated Strategies for Synthetic Mimicking of Protein Binding Sites," <i>FEBS Eur J Biochem.</i> 145(1):1-20.
	31.	Austgulen, R. et al. (1987). "Fibroblast Growth-Stimulatory Activity Released from Human Monocytes," <i>Scand. J. Immunol.</i> 26:621-629.
	32.	Avrameas, S. et al. (1971). "Communication to the Editors: Peroxidase Labelled Antibody and Fab Conjugates with Enhanced Intracellular Penetration," <i>Immunochemistry</i> 8:1175-1179.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

33.	Barlow, D.J. et al. (August 21, 1986). "Continuous and Discontinuous Protein Antigenic Determinants," <i>Nature</i> 322:747-748.
34.	Bates, E.J. et al. (July 1995). "Inhibitory Effects of Arachidonic Acid (20:4,n-6) and its Monohydroperoxy- and Hydroxy-Metabolites on Procoagulant Activity in Endothelial Cells," <i>Atherosclerosis</i> 116:125-133.
35.	Bazzoni, F. et al. (1995). "How Do Tumor Necrosis Factor Receptors Work," <i>J. Inflamm.</i> 45:221-238.
36.	Berkow, R.L. et al. (December 1, 1987). "Enhancement of Neutrophil Superoxide Production by Preincubation with Recombinant Human Tumor Necrosis Factor," <i>J. Immunology</i> 139(11):3783-3791.
37.	Bernstein, C.N. et al. (2001). "Cancer Risk in Patients with Inflammatory Bowel Disease," <i>Cancer</i> 91:854-862.
38.	Bès, C. et al. (April 18, 2003). "Mapping the Paratope of Anti-CD4 Recombinant Fab 13B8.2 by Combining Parallel Peptide Synthesis and Site-Directed Mutagenesis," <i>The J. of Biol. Chem.</i> 278(16):14265-14273.
39.	Beutler, B. et al. (1989). "The Biology of Cachectin/TNF - A Primary Mediator of the Host Response," <i>Ann. Rev. Immunol.</i> 7:625-655.
40.	Bhardwaj, V. et al. (August 1992). "Subjugation of Dominant Immunogenic Determinants Within a Chimeric Peptide," <i>Eur. J. Immunol.</i> 22(8):2009-2016.
41.	Bittorf, T. (2000). "cDNA Cloning and Functional Analysis of a Truncated STAT5a Protein from Autonomously Growing FDCP-1 Cells," <i>Cell Signal</i> 12:721-730.
42.	Bloom, J.W. et al. (September 1, 1993). "Epitope Mapping and Functional Analysis of Three Murine IgG1 Monoclonal Antibodies to Human Tumor Necrosis Factor- α ," <i>J. Immunol.</i> 151(5):2707-2716.
43.	Bodmer, J.-L. et al. (January 2002). "The Molecular Architecture of the TNF Superfamily," <i>Trends Biochem Sci.</i> 27(1):19-26.
44.	Bradbury, A. et al. (1995). "The Cloning of Hybridoma V Regions for Their Ectopic Expression in Intracellular and Intercellular Immunization," Chapter 10 In <u>Antibody Engineering</u> Borrebaeck, C.A.K. ed., IRL Press: Oxford, UK pp. 295-361.
45.	Briscoe, H. et al. (October 2003). "A Novel Tumor Necrosis Factor (TNF) Mimetic Peptide Prevents Recrudescence of <i>Mycobacterium bovis</i> Bacillus Calmette-Guerin (BCG) Infection in CD4 $^{+}$ T Cell-Depleted Mice," <i>J. Leukoc. Biol.</i> 68:538-544.
46.	Britton, W.J. et al. (May 1998). "A Tumor Necrosis Factor Mimetic Peptide Activates a Murine Macrophage Cell Line to Inhibit Mycobacterial Growth in a Nitric Oxide-Dependent Fashion," <i>Infection and Immunity</i> 66(5):2122-2127.
47.	Burrows, S.R. et al. (January 1992). "The Specificity of Recognition of a Cytotoxic T Lymphocyte Epitope," <i>Eur. J. Immunol.</i> 22(1):191-195.
48.	Burton, D.R. et al. (November 27, 1980). "The C1q Receptor Site on Immunoglobulin G," <i>Nature</i> , 288:338-344.
49.	Carswell, E.A. et al. (September 1975). "An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors," <i>Proc. Natl. Acad. Sci. USA</i> 72(9):3666-3670.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

	50.	Chen, Y. et al. (November 1999). "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> 293:865-881.
	51.	Choulier, L. et al. (2001). "Delineation of a Linear Epitope by Multiple Peptide Synthesis and Phage Display," <i>Journal of Immunological Methods</i> 249:253-264.
	52.	Connolly, M.L. (June 1993). "The Molecular Interface Package," <i>J. Mol. Graphics</i> 11:139-141.
	53.	Cook, K.M. et al. (1985). "Topographic and Functional Assay of Antigenic Determinants of Human Prolactin with Monoclonal Antibodies," <i>Molec. Immun.</i> 22(7):795-801.
	54.	Corey, E. et al. (1997). "Prostate-Specific Antigen: Characterization of Epitopes by Synthetic Peptide Mapping and Inhibition Studies," <i>Clin. Chemistry</i> 43(4):575-584.
	55.	Corti, A. et al. (1992). "Antigenic Regions of Tumor Necrosis Factor Alpha and Their Topographic Relationships with Structural/Functional Domains," <i>Mol. Immunol.</i> 29(4):471-479.
	56.	Corti, A. et al. (1993). "Evidences That Syngeneic Alpha-Type Anti-Idiotypic Antibodies May Non-Competitively Inhibit Idiotype/Oligomeric Antigen Interactions by Affecting Idiotype Avidity," <i>Mol. Immunol.</i> 30(12):1123-1131.
	57.	Costabile, M. et al. (October 1, 2001). "A Novel Long Chain Polyunsaturated Fatty Acid, β -Oxa 21:3n-3, Inhibits T Lymphocyte Proliferation, Cytokine Production, Delayed-Type Hypersensitivity, and Carrageenan-Induced Paw Reaction and Selectively Targets Intracellular Signals," <i>J. Immunol.</i> 167(7):3980-3987.
	58.	Craig, L. et al. (1998). "The Role of Structure in Antibody Cross-Reactivity Between Peptides and Folded Proteins," <i>J. Mol. Biol.</i> 281:183-201.
	59.	Danis, V.A. et al. (July 1991). "Effects of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), IL-2, Interferon-Gamma (IFN- γ), Tumour Necrosis Factor-Alpha (TNF- α) and IL-6 on the Production of Immunoreactive IL-1 and TNF- α by Human Monocytes," <i>Clin. Exp. Immunol.</i> 85(1):143-150.
	60.	Danis, V.A. et al. (August 1992). "Circulating Cytokine Levels in Patients with Rheumatoid Arthritis: Results of a Double Blind Trial with Sulphasalazine," <i>Ann Rheum Dis.</i> 51(8):946-950.
	61.	deHaard, H.J.W. et al. (September 1998). "Selection of Recombinant, Library-Derived Antibody Fragments Against p24 for Human Immunodeficiency Virus Type 1 Diagnostics," <i>Clin. Diagn. Lab. Immunol.</i> 5(5):636-644.
	62.	Diamond, A.G. et al. (1984). "Localized Conformational Changes Induced in a Class I Major Histocompatibility Antigen by the Binding of Monoclonal Antibodies," <i>J. Immun.</i> 132(3):1169-1175.
	63.	Dionyssopoulou, H. et al. (July 31, 2000). "Synthetic Peptides as Putative Therapeutic Agents in Transplantation Medicine: Application of PEPSCAN to the Identification of Functional Sequences in the Extracellular Domain of the Interleukin-2 Receptor Beta Chain (IL-2R β)," <i>J. Immunol. Methods</i> 241:83-95.
	64.	Dong, L. et al. (2003). "Human CD30: Structural Implications From Epitope Mapping and Modeling Studies," <i>J. Mol. Recogn.</i> 16:28-36.
	65.	Duncan, A.R. et al. (April 7, 1988). "Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG," <i>Nature</i> 332: 563-564.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

66.	Eck, M. J. et al. (September 15, 1988). "Crystallization of Trimeric Recombinant Human Tumor Necrosis Factor (Cachectin)," <i>J. Biol. Chem.</i> 263(26):12816-12819.
67.	Eck, M.J. (October 1990). "The Three-Dimensional Structure of Tumor Necrosis Factor (TNF- α) at 2.6 Å Resolution Dallas," <i>Dissertation - University of Texas Southwestern Medical Center</i> : Dallas, TX pp. 1-213.
68.	Edmundson, A.B. et al. (1991). "Binding of Peptides to Proteins: An Exercise in Molecular Design," <i>Ciba Found. Symp.</i> 158:213-225; Discussion pp. 225-230.
69.	Edmundson, A.B. et al. (July 1993). "Principles and Pitfalls in Designing Site-Directed Peptide Ligands," <i>Proteins</i> 16(3):246-267.
70.	Ewing, C. et al. (May 1, 1990). "Antibody Activity in Ankylosing Spondylitis Sero To Two Sites on HLA B27.1 at the MHC Groove Region (Within Sequence 65-85), and to a Klebsiella Pneumoniae Nitrogenase Reductase Peptide (Within Sequence 181-199)," <i>J. Exp. Med.</i> 171(5):1635-1647.
71.	Felici, F. et al. (June 15, 1993). "Mimicking of Discontinuous Epitopes by Phage-Displayed Peptides. II. Selection of Clones Recognized by a Protective Monoclonal Antibody Against the <i>Bordetella pertussis</i> Toxin From Phage Peptide Libraries," <i>Gene</i> 128(1):21-27.
72.	Ferrante, A. et al. (November 1, 1993). "Killing of <i>Staphylococcus aureus</i> by Tumor Necrosis Factor- α -Activated Neutrophils. The Role of Serum Opsonins, Integrin Receptors, Respiratory Burst, and Degranulation," <i>J. Immunol.</i> 151(9):4821-4828.
73.	Ferrante, A. et al. (April 15, 1994). "Interaction of <i>Staphylococcus aureus</i> with Human Neutrophils and the Down-Regulation of TNF Receptors," <i>J. Immunol.</i> 152(8):3998-4004.
74.	Ferrante, J.V. et al. (March 1997). "Altered Responses of Human Macrophages to Lipopolysaccharide by Hydroperoxy Eicosatetraenoic Acid, Hydroxy Eicosatetraenoic Acid, and Arachidonic Acid," <i>J. Clin. Invest.</i> 99:1445-1452.
75.	Fersht, A.R. et al. (March 21, 1985). "Hydrogen Bonding and Biological Specificity Analysed by Protein Engineering," <i>Nature</i> 314:235-238.
76.	Fieser, T.M. et al. (December, 1987). "Influence of Protein Flexibility and Peptide Conformation on Reactivity of Monoclonal Anti-Peptide Antibodies with a Protein α -Helix," <i>Proc. Natl. Acad. Sci. USA</i> 84:8568-8572.
77.	Finkelman, F.D. et al. (August 1, 1993). "Anti-Cytokine Antibodies as Carrier Proteins. Prolongation of in Vivo Effects of Exogenous Cytokines by Injection of Cytokine-Anti-Cytokine Antibody Complexes," <i>J. Immunol.</i> 151(3):1235-44.
78.	Forest, K.T. et al. (February 1996). "Assembly and Antigenicity of the <i>Neisseria Gonorrhoeae</i> Pilus Mapped with Antibodies," <i>Infect. Immun.</i> 64(2):644-652.
79.	Frank, R. (1992). "Spot-Synthesis: An Easy Technique For the Positionally Addressable, Parallel Chemical Synthesis on a Membrane Support," <i>Tetrahedron</i> 48(42):9217-9232.
80.	Franklin, M.C. et al. (April 2004). "Insights Into ErbB Signaling From the Structure of the ErbB2-pertuzumab Complex," <i>Cancer Cell</i> 5:317-328.
81.	Fransen, L. et al. (1986). "Recombinant Tumor Necrosis Factor: its Effect and its Synergism with Interferon- γ on a Variety of Normal and Transformed Human Cell Lines," <i>Eur. J. Cancer. Clin. Oncol.</i> 22(4):419-426.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

82.	Fransen, L. et al. (1986). "Recombinant Tumor Necrosis Factor: Species Specificity for a Variety of Human and Murine Transformed Cell Lines," <i>Cell. Immunol.</i> 100:260-267.
83.	Gao, B. et al. (July 1, 1996). "Multiple Interactive Residues of Recognition - Elucidation of Discontinuous Epitopes with Linear Peptides," <i>J. Immunol.</i> 157(1):183-188.
84.	GenBank Accession No. P16753, created on August 1, 1990, located at < http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=139232 > last visited on December 6, 2004, five pages.
85.	Getzoff, E.D. et al. (March 6, 1987). "Mechanisms of Antibody Binding to a Protein," <i>Science</i> 235:1191-1196.
86.	Getzoff, E.D. et al. (1988). "The Chemistry and Mechanism of Antibody Binding to Protein Antigens," <i>Advances in Immunology</i> 43:1-98.
87.	Geysen, H.M. (1985). "Antigen-Antibody Interactions at the Molecular Level: Adventures in Peptide Synthesis," <i>Immunology Today</i> 6:364-369.
88.	Geysen, H.M. et al. (January 1985). "Small Peptides Induce Antibodies with a Sequence and Structural Requirement for Binding Antigen Comparable to Antibodies Raised Against the Native Protein," <i>Proc. Natl. Acad. Sci. USA</i> 82(1):178-182.
89.	Geysen, H.M. et al. (1986). "The Delineation of Peptides Able to Mimic Assembled Epitopes," <i>In Synthetic Peptides as Antigens</i> : Ciba Found Symp. John Wiley & Sons, Inc. 119:130-149.
90.	Geysen, H.M. et al. (1987). "Chemistry of Antibody Binding to a Protein," <i>Science</i> 235:1184-1190.
91.	Geysen, H.M. et al. (1988). "A Synthetic Strategy for Epitope Mapping" <i>In Peptides: Chemistry and Biology, Proceedings of the Tenth American Peptide Symposium</i> May 23-28, 1987, St. Louis MO, Marshall, G.R. ed. ESCOM Science Publishers: The Netherlands, pp. 519-523.
92.	Gilbert, D. et al. (1995). "An Idiotype D23-Bearing Polyspecific, Murine Anti-DNA Monoclonal Antibody Forms Glomerular Immune Deposits. Pathogenic Role of Natural Autoantibodies," <i>Molecular Immunology</i> 32(7):477-486.
93.	Gomme, P.T. et al. (September 1999). "Characterization of Epitope Regions of Thyrotropin β -Subunit Recognized by the Monoclonal Antibodies mAb279 and mAb299: A Chimeric Peptide Approach," <i>J. Pept. Res.</i> 54(3):218-229.
94.	Granier, C. et al. (1989). "Review: The Antigenic Structure of a Scorpion Toxin," <i>Molecular Immunology</i> 26(6):503-513.
95.	Haak-Frendscho, M. et al. (February 1994). "Inhibition of TNF by a TNF Receptor Immunoadhesin. Comparison to an Anti-TNF Monoclonal Antibody," <i>J. Immunol.</i> 152:1347-1353.
96.	Hanauer, S.B. et al. (May 4, 2002). "Maintenance Infliximab for Crohn's Disease: The ACCENT I Randomised Trial," <i>Lancet</i> 359:1541-1549.
97.	Hawkins, R.E. et al. (1993). "The Contribution of Contact and Non-Contact Residues of Antibody in the Affinity of Binding to Antigen. The Interaction of Mutant D1.3 Antibodies with Lysozyme," <i>J. Mol. Biol.</i> 234:958-964.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 7, 2004	

98.	Hayder, H. et al. (1999). "Adenovirus-Induced Liver Pathology is Mediated Through TNF Receptors I and II but Is Independent of TNF or Lymphotoxin," <i>J. Immunology</i> 163:1516-1520.
99.	Hilpert, K. et al. (2000). "Characterizing and Optimizing Protease/Peptide Inhibitor Interactions, a New Application for Spot Synthesis," <i>J. Biochem. (Tokyo)</i> 128:1051-1057.
100.	Hohmann, H-P. et al. (September 5, 1990). "Tumor Necrosis Factors- α and - β Bind to the Same Two Types of Tumor Necrosis Factor Receptors and Maximally Activate the Transcription Factor NF- κ B at Low Receptor Occupancy and Within Minutes after Receptor Binding," <i>J. Biol. Chem.</i> 265:15183-15188.
101.	Hoogenboom, H.R. et al. (1999). "Selection-Dominant and Nonaccessible Epitopes on Cell-Surface Receptors Revealed by Cell-Panning with a Large Phage Antibody Library," <i>Eur. J. Biochem.</i> 260:774-784.
102.	Hopp, T.P. et al. (June 1981). "Prediction of Protein Antigenic Determinants from Amino Acid Sequences," <i>Proc. Natl. Acad. Sci. USA</i> 78(6):3824-3828.
103.	Huang, X. et al. (1991). "A Time-Efficient, Linear-Space Local Similarity Algorithm," In <u>Advances in Applied Mathematics</u> Academic Press, Inc. 12(1):337-357.
104.	Israel, S. et al. (1986). "Binding of Human TNF- α to High-Affinity Cell Surface Receptors: Effect of IFN," <i>Immunol. Lett.</i> 12:217-224.
105.	Jameson, B.A. et al. (June 3, 1988). "Location and Chemical Synthesis of a Binding Site for HIV-1 on the CD4 Protein," <i>Science</i> 240:1335-1339.
106.	Jersmann, H.P.A. et al. (April 1998). "Enhancement of Lipopolysaccharide-Induced Neutrophil Oxygen Radical Production by Tumor Necrosis Factor Alpha," <i>Infection and Immunity</i> 66(4):1744-1747.
107.	Jia, X-C. et al. (2004). "A Novel Method of Multiplexed Competitive Antibody Binning for the Characterization of Monoclonal Antibodies," <i>J. Immunol. Methods</i> 288:91-98.
108.	Jin, L. et al. (1992). "High Resolution Functional Analysis of Antibody-Antigen Interactions," <i>J. Mol. Biol.</i> 226:851-865.
109.	Jones, M. et al. (1996). "Does Exposure to Immunosuppressive Therapy Increase the 10 Year Malignancy and Mortality Risks in Rheumatoid Arthritis? A Matched Cohort Study," <i>British Journal of Rheumatology</i> 35:738-745.
110.	Josephson, K. et al. (July 2002). "Noncompetitive Antibody Neutralization of IL-10 Revealed by Protein Engineering and X-Ray Crystallography," <i>Structure</i> 10:981-987.
111.	Karpusas, M. et al. (April 2001). "Structure of CD40 Ligand in Complex with the Fab Fragment of a Neutralizing Humanized Antibody," <i>Structure</i> 9:321-329.
112.	Korth, C. et al. (November 6, 1997). "Prion (PrP ^{Sc})-Specific Epitope Defined by a Monoclonal Antibody," <i>Nature</i> 390:74-77.
113.	Kramer, A. (1997). "Molecular Basis of Binding Promiscuity of an Anti-p24 (HIV-1) Monoclonal Antibody," <i>Cell</i> 91:799-809.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

114.	Kramer, A. et al. (1995). "A General Route to Fingerprint Analyses of Peptide-Antibody Interactions Using a Clustered Amino Acid Peptide Library: Comparison with a Phage Display Library," <i>Mol. Immunol.</i> 32(7):459-465.
115.	Kull, F.C. et al. (September 1985). "Cellular Receptor for ^{125}I -Labeled Tumor Necrosis Factor: Specific Binding, Affinity Labeling, and Relationship to Sensitivity," <i>Proc. Natl. Acad. Sci. USA</i> 82:5756-5760.
116.	Kumaratilake, L.M. et al. (May 1995). "A Synthetic Tumor Necrosis Factor- α Agonist Peptide Enhances Human Polymorphonuclear Leukocyte-Mediated Killing of <i>Plasmodium falciparum</i> in Vitro and Suppresses <i>Plasmodium chabaudi</i> Infection in Mice," <i>J. Clin. Invest.</i> 95:2315-2323.
117.	Labrousse, H. et al. (1997). "Effect of Temperature on the Reactivities of Polyreactive and Monospecific Monoclonal IgC Antibodies," <i>Res. Immunol.</i> 148:267-276.
118.	Langedijk, J.P.M. et al. (1990). "Location of Epitopes on the Major Core Protein p24 of Human Immunodeficiency Virus," <i>J. Gen. Virol.</i> 71:2609-2614.
119.	Langeveld, J.P.M. et al. (2001). "Characterisation of a Protective Linear B Cell Epitope Against Feline Parvoviruses," <i>Vaccine</i> 19:2352-2360.
120.	Laster, A.J. et al. (August 1987). "Polyspecific Reactivity of a Murine Monoclonal Antibody That Binds to Nuclear Matrix-Associated, Chromatin-Bound Autoantigens," <i>Clin. Immunol. Immunopathol.</i> 44(2):187-205.
121.	Lidbury, B.A. (April 1993). "The Enhancement of Human Tumor Necrosis Factor- α Antiviral Activity <i>In Vivo</i> by Monoclonal and Specific Polyclonal Antibodies," <i>Lymphokine Cytokine Res.</i> 12(2):69-74.
122.	Lidbury, B.A. et al. (1994). "The Effect of Enhancing Antibodies on TNF Interactions with its Specific Receptor: Consequences for <i>In Vitro</i> TNF Antiviral Activity," <i>Biotechnol. Ther.</i> 5(1-2):27-45.
123.	Liu, Z. et al. (1999). "Fine Mapping of the Antigen-Antibody Interaction of scFv217, are Combinant Antibody Inhibiting RNA Polymerase From Drosophila. Melanogaster," <i>J. Mol. Recognit.</i> 12:103-111.
124.	Llanos, R. et al. (1999). "Tubulin Binding Sites on γ -Tubulin: Identification and Molecular Characterization," <i>Biochemistry</i> 38:15712-15720.
125.	Loetscher, H. et al. (November 25, 1990). "Purification and Partial Amino Acid Sequence Analysis of Two Distinct Tumor Necrosis Factor Receptors from HL60 Cells," <i>J. Biol. Chem.</i> 265(33):20131-20138.
126.	MacCallum, R.M. et al. (1996). <i>J. Mol. Biol.</i> 262:732-745.
127.	Mack, P. et al. (December 1991). "The Use of Peptides as Therapeutics & Vaccines," <i>Australas. Biotechnol.</i> 1(3):160-163. (Rathjen PubMed 106/04.)
128.	Maeji, N.J. et al. (May-June 1991). "Systematic Screening for Bioactive Peptides," <i>Pept. Res.</i> 4(3):142-146.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
PTO/SB/ 08 (2-92) pa- 940882	Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 7, 2004	

129.	Maini, R.N. et al. (1998). "Therapeutic Efficacy of Multiple Intravenous Infusions of Anti-Tumor Necrosis Factor α Monoclonal Antibody Combined with Low-Dose Weekly Methotrexate in Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> 41(9):1552-1563.
130.	Meulenberg, J.J.M. et al. (1998). "Localization and Fine Mapping of Antigenic Sites on the Nucleocapsid Protein N of Porcine Reproductive and Respiratory Syndrome Virus with Monoclonal Antibodies," <i>Virology</i> 252:106-114.
131.	Molina, F. et al. (May/June, 1996) "Improved Performances of Spot Multiple Peptide Synthesis," <i>Peptide Research</i> 9(3):151-155.
132.	Montero-Julian, F.A. et al. (February 15, 1995). "Pharmacokinetic Study of Anti-Interleukin-6 (IL-6) Therapy With Monoclonal Antibodies: Enhancement of IL-6 Clearance by Cocktails of Anti-IL-6 Antibodies," <i>Blood</i> 85(4):917-924.
133.	Muso, E. et al. (March 1987). "A Polyspecific Monoclonal Anti-DNA Autoantibody Also Binds to Cell-Surface Protein(s)," <i>Clin. Immunol. Immunopathol.</i> 42(3):370-374.
134.	Mutter, M. et al. (1986). "Approaches to Synthetic Vaccines: Design of Epitope-Containing Amphiphilic Peptides Matching the Antigenic Structure in the Native Protein," <i>Helv. Chim. Acta</i> 69:985-995.
135.	Mutuberria, R. et al. (2004). "Isolation of Human Antibodies to Tumor-Associated Endothelial Cell Markers by in vitro Human Endothelial Cell Selection with Phage Display Libraries," <i>J. Immunol. Methods</i> 287:31-47.
136.	Nagahira, K. et al. (1995). "Epitope Mapping of Monoclonal Antibodies to Tumor Necrosis Factor- α by Synthetic Peptide Approach," <i>Immunol. Letters</i> 46:135-141.
137.	Nagaoka, M. et al. (2003). "Single Amino Acid Substitution in the Mouse IgG1 Fc Region Induces Drastic Enhancement of the Affinity to Protein A," <i>Protein Engineering</i> 16(4):243-245.
138.	Naismith, J.H. et al. (1996). "Seeing Double: Crystal Structures of the Type I TNF Receptor," <i>J. Mol. Recognition</i> 9:113-117.
139.	Naismith, J.H. et al. (February 1998). "Modularity in the TNF-Receptor Family," <i>Trends Biochem. Sci.</i> 23:74-79.
140.	Nanda, N.K. et al. (August 1, 1995). "Recognition of Multiple Peptide Cores by a Single T Cell Receptor," <i>J. Exp. Med.</i> 182(2):531-539.
141.	Nawroth, P. et al. (1988). "Tumor Necrosis Factor/Cachectin-Induced Intravascular Fibrin Formation in Meth A Fibrosarcomas," <i>J. Exp. Med.</i> 168:637-647.
142.	Niedrig, M. et al. (1992). "Inhibition of Viral Replication by Monoclonal Antibodies Directed Against Human Immunodeficiency Virus gp120," <i>J. Gen. Virol.</i> 73:2451-2455.
143.	Nishihara, T. et al. (2001). "Humanization and Epitope Mapping of Neutralizing Anti-Human Fas Ligand Monoclonal Antibodies: Structural Insights into Fas/Fas Ligand Interaction," <i>J. Immunol.</i> 167:3266-3275.
144.	Nissen-Meyer, J. et al. (1987). "Effect of Antisera Against Recombinant Tumor Necrosis Factor and the Monocyte-Derived Cytotoxin(s) on Monocyte-Mediated Killing of Various Tumor Cells," <i>Cell. Immunol.</i> 109:384-396.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 273402602309	Application Number 10/702,681
		Applicant	Deborah A. RATHJEN et al.
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 7, 2004	

145.	Notredame, C. et al. (September 8, 2000). "T-Coffee: A Novel Method for Fast and Accurate Multiple Sequence Alignment," <i>J. Mol. Biol.</i> 302(1):205-217.
146.	Old, L.J. (November 8, 1985). "Tumor Necrosis Factor (TNF)," <i>Science</i> 230:630-632.
147.	Parry, N.R. et al. (1989). "Neutralizing Epitopes of Type O Foot-and-Mouth Disease Virus. II. Mapping Three Conformational Sites with Synthetic Peptide Reagents," <i>J Gen Virol.</i> 70:1493-1503.
148.	Pless, J. et al. (1973). "Boron Tris(trifluoroacetate) for Removal of Protecting Groups in Peptide Chemistry," <i>Angew Chem. Int. Ed. Engl.</i> 12(2):147-148.
149.	Present, D.H. et al. (May 6, 1999). "Infliximab For the Treatment of Fistulas in Patients with Crohn's Disease," <i>The New England Journal of Medicine</i> 340:1398-1405.
150.	Prodinger, W.M. et al. (1998). "Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21)," <i>J. Immunol.</i> 161:4604-4610.
151.	Ramasamy, R. et al. (September 1990). "Novel Cross-Reactive Epitopes on Asexual Blood Stage Antigens of <i>Plasmodium falciparum</i> ," <i>Parasite Immunol.</i> 12(5):457-471.
152.	Rathjen, D.A. et al. (June 1992). "Selective Enhancement of the Tumour Necrotic Activity of TNF, with Monoclonal Antibody," <i>Br. J. Cancer</i> 65(6):852-856.
153.	Rathjen, D.A. et al. (1993). "Selective Enhancement of Tumour Necrosis Factor Activity: Mapping Regions with Monoclonal Antibodies," <i>Bioorganic & Medicinal Chemistry Letters</i> 3(3):457-462.
154.	Reece, J.C. et al. (December 1, 1993). "Mapping the Major Human T Helper Epitopes of Tetanus Toxin: The Emerging Picture," <i>J. Immunol.</i> 151(11):6175-6184.
155.	Reece, J.C. et al. (June 24, 1994). "Scanning for T Helper Epitopes with Human PBMC using Pools of Short Synthetic Peptides," <i>J. Immunol. Methods</i> . 172(2):241-254.
156.	Reineke, U. et al. (May 1996). "Mapping Protein-Protein Contact Sites Using Cellulose-Bound Peptide Scans," <i>Mol. Divers.</i> 1(3):141-148.
157.	Reineke, U. et al. (1998). "Mapping of the Interleukin-10/interleukin-10 Receptor Combining Site," <i>Protein Science</i> 7:951-960.
158.	Reineke, U. et al. (1999). "Evidence for Conformationally Different States of Interleukin-10: Binding of a Neutralizing Antibody Enhances Accessibility of a Hidden Epitope," <i>J. Mol. Recognition</i> 12:242-248.
159.	Reineke, U. et al. (March 1999). "A Synthetic Mimic of a Discontinuous Binding Site on Interleukin-10," <i>Nature Biotechnol.</i> 17:271-275.
160.	Reineke, U. et al. (2001). "Epitope Mapping with Synthetic Peptides Prepared by SPOT Synthesis," <i>In Antibody Engineering</i> (Springer Lab Manual) Kontermann/Dubel eds. pp. 433-459.
161.	Roach, D.R. et al. (October 1999). "Tumor Necrosis Factor (TNF) and a TNF-Mimetic Peptide Modulate the Granulomatous Response to <i>Mycobacterium bovis</i> BCG Infection In Vivo," <i>Infection and Immunity</i> 67(10):5473-5476.
162.	Robinson, B.S. et al. (1999). "Effects of β -Oxa and β -Thia Polyunsaturated Fatty Acids on Agonist-Induced Increase in Endothelial Cell Adhesion Molecules," <i>Lipids</i> 34 Suppl:S341-S342.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 273402602309	Application Number 10/702,681
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 7, 2004	

163.	Rodseth, L.E. et al. (June 3, 1994). "Two Crystal Forms of the Extracellular Domain of Type I Tumor Necrosis Factor Receptor," <i>J. Mol. Biol.</i> 239(2):332-335.
164.	Ruff, M.R. et al. (January 1981). "Rabbit Tumor Necrosis Factor: Mechanism of Action," <i>Infect. Immun.</i> 31(1):380-385.
165.	Sato, N. et al. (June 1986). "Actions of Tumor Necrosis Factor on Cultured Vascular Endothelial Cells: Morphologic Modulation, Growth Inhibition, and Cytotoxicity," <i>JNCI</i> 76(6):1113-1121.
166.	Sattayasai, N. et al. (September 1991). "Subtype-Specificity of Antipeptide Antibodies Raised Against Unique Sequences of Human Interferons- α ," <i>Mol. Immunol.</i> 28(9):975-983.
167.	Scallan, B. et al. (May 2004). "Addition of an Extra Immunoglobulin Domain to Two Anti-Rodent TNF Monoclonal Antibodies Substantially Increased Their Potency," <i>Mol. Immunol.</i> 41(1):73-80.
168.	Scanlan, C.N. et al. (July, 2002). "The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α 1-2 Mannose Residues on the Outer Face of gp120," <i>Journal of Virology</i> 76(14):7306-7321.
169.	Scheurich, P. et al. (1986). "Quantification and Characterization of High-Affinity Membrane Receptors for Tumor Necrosis Factor on Human Leukemic Cell Lines," <i>Int. J. Cancer</i> 38:127-133.
170.	Schlayer, H.-J. et al. (1987). "Enhancement of Neutrophil Adherence to Isolated Rat Liver Sinusoidal Endothelial Cells by Supernatants of Lipopolysaccharide-Activated Monocytes," <i>J. Hepatol.</i> 5:311-321.
171.	Schmidt, T. (1996). "Molecular Interaction Between the Strep-Tag Affinity Peptide and its Cognate Target, Streptavidin," <i>J. Mol. Biol.</i> 255:753-766.
172.	Schoofs, P.G. et al. (January 15, 1988). "Epitopes of an Influenza Viral Peptide Recognized by Antibody at Single Amino Acid Resolution," <i>J. Immunol.</i> 140(2):611-616.
173.	Schreiber, M. et al. (December 1997). "The V3-Directed Immune Response in Natural Human Immunodeficiency Virus Type 1 Infection is Predominantly Directed Against a Variable, Discontinuous Epitope Presented by the gp120 V3 Domain," <i>J. Virol.</i> 71(12):9198-9205.
174.	Selvey, L.A. et al. (November 1, 1990). "Identification of B-Epitopes in the Human Papillomavirus 18 E7 Open Reading Frame Protein," <i>J. Immunol.</i> 145(9):3105-3110.
175.	Shukla, D.D. et al. (November 1989). "Localization of Virus-Specific and Group-Specific Epitopes of Plant Potyviruses by Systematic Immunochemical Analysis of Overlapping Peptide Fragments," <i>Proc. Natl. Acad. Sci. USA</i> 86(21):8192-8196.
176.	Slootstra, J.W. et al. (1995). "Structural Aspects of Antibody-Antigen Interaction Revealed Through Small Random Peptide Libraries," <i>Molecular Diversity</i> 1:87-96.
177.	Slootstra, J.W. et al. (October 1995). "Possible Active Site of the Sweet-Tasting Protein Thaumatin," <i>Chem. Senses</i> 20:535-543.
178.	Slootstra, J.W. et al. (1996). "Identification of New Tag Sequences with Differential and Selective Recognition Properties for the Anti-FLAG Monoclonal Antibodies M1, M2, and M5," <i>Mol. Divers.</i> 2:156-164.
179.	Slootstra, J.W. et al. (October 1997). "Screening of a Small Set of Random Peptides: A New Strategy to Identify Synthetic Peptides that Mimic Epitopes," <i>J. Mol. Recognit.</i> 10:217-224.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 7, 2004	

180.	Sluyser, M. et al. (1992). "Influence of Estrogen Receptor Variants in Mammary Carcinomas on the Prognostic Reliability of the Receptor Assay," <i>Mol. & Cell. Endocrinol.</i> 85:83-88.
181.	Smith, R.A. et al. (November 15, 1986). "Species Specificity of Human and Murine Tumor Necrosis Factor," <i>J. Biol. Chem.</i> 261(32):14871-14874.
182.	Smith, R.A. et al. (May 25, 1987). "The Active Form of Tumor Necrosis Factor is a Trimer," <i>J. Biol. Chem.</i> 262(15):6951-6954.
183.	Snijders, A. et al. (1991). "Identification of Linear Epitopes on Semliki Forest Virus E2 Membrane Protein and Their Effectiveness as a Synthetic Peptide Vaccine," <i>J. Gen Virol.</i> 72:557-565.
184.	Sprang, S.R. et al. (1990). "Subunit Interactions and the Function of Tumor Necrosis Factor" Chapter 35 In <u>Current Research in Protein Chemistry: Techniques, Structure, Function</u> Villafranca, J. J. ed. Academic Press, Inc.: San Diego, CA pp. 383-394.
185.	Sprang, S.R. et al. (1992). "The 3-D Structure of TNF" Chapter 2 In <u>Tumor Necrosis Factors: The Molecules and Their Emerging Role In Medicine</u> Beutler, B. ed. Raven Press Ltd.: New York, NY pp. 11-32.
186.	Stanfield, R.L. et al. (1995). "Protein-Peptide Interactions," <i>Curr. Opin. Struc. Biol.</i> 5:103-113.
187.	Stigler, R. et al. (1995). "Interaction Between a Fab Fragment Against gp41 of Human Immunodeficiency Virus 1 and its Peptide Epitope: Characterization Using a Peptide Epitope Library and Molecular Modeling," <i>Protein Eng.</i> 8:471-479.
188.	Sugarman, B.J. et al. (November 22, 1985). "Recombinant Human Tumor Necrosis Factor- α Effects on Proliferation of Normal and Transformed Cells in Vitro," <i>Science</i> 230:943-945.
189.	Tempest, P.R. et al. (June 1994). "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> 13(3):183-190.
190.	ten Hove, T. et al. (2002). "Infliximab Treatment Induces Apoptosis of Lamina Propria T Lymphocytes in Crohn's Disease," <i>Gut</i> 50:206-211.
191.	Timmerman, P. et al. (2004). "Mapping of a Discontinuous and Highly Conformational Binding Site on Follicle Stimulating Hormone Subunit-Beta (FSH-Beta) Using Domain Scan and Matrix Scan Technology," <i>Mol. Divers.</i> 8:61-77.
192.	Tindle, R.W. et al. (June 1990). "Identification of B Epitopes in Human papillomavirus Type 16 E7 Open Reading Frame Protein," <i>J. Gen. Virol.</i> 71(Pt. 6):1347-1354.
193.	Triantafyllou, B. et al. (Aug-Dec. 1992). "Use of the Multipin Peptide Synthesis Technique for the Generation of Antipeptide Seras," <i>Cell Biophys.</i> 21(1-3):33-52.
194.	Tribbick, G. et al. (June 3, 1991). "Systematic Fractionation of Serum Antibodies Using Multiple Antigen Homologous Peptides as Affinity Ligands," <i>J. Immunol. Methods.</i> 139(2):155-166.
195.	Truyens, C. et al. (November 1999). "The Endogenous Balance of Soluble Tumor Necrosis Factor Receptors and Tumor Necrosis Factor Modulates Cachexia and Mortality in Mice Acutely Infected with <i>Trypanosoma cruzi</i> ," <i>Infect Immun.</i> 67:5579-5586.
196.	Vajdos, F.F. et al. (2002). "Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," <i>J. Mol. Biol.</i> 320:415-428.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 273402602309	Application Number 10/702,681
		Applicant Deborah A. RATHJEN et al.	
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

197.	Valle, M. et al. (1999). "Selection of Antibody Proves to Correlate Protein Sequence Domains with Their Structural Distribution," <i>Prot. Sci.</i> 8:883-889.
198.	Van Amerongen, A. et al. (1994). "Design of Peptides With Improved Affinities for Anti-Human Chorionic Gonadotropin Monoclonal Antibodies," <i>Peptide Res.</i> 7(2):83-90.
199.	Van der Goot, F.G. et al. (1999). "Membrane Interaction of TNF is not Sufficient to Trigger Increase in Membrane Conductance in Mammalian Cells," <i>FEBS Lett.</i> 460:107-111.
200.	Van der Heijde, D.M.F.M. et al. (January 1992). "Biannual Radiographic Assessments of Hands and Feet in a Three-Year Prospective Followup of Patients With Early Rheumatoid Arthritis," <i>Arthritis and Rheumatism</i> 35(1):26-34.
201.	Van Dolleweerd, C.J. et al. (May 21, 2004). "Peptide Mapping of a Novel Discontinuous Epitope of the Major Surface Adhesion From <i>Streptococcus mutans</i> ," <i>The Journal of Biological Chemistry</i> 279(21):22198-22203.
202.	van Regenmortel, M.H.V. (1989). "Structural and Functional Approaches to the Study of Protein Antigenicity," <i>Immunology Today</i> 10(8):266-272.
203.	van Regenmortel, M.H.V. (1989). "The Concept and Operational Definition of Protein Epitopes," <i>Phil. Trans. R. Soc. Lond. B</i> 323:451-466.
204.	Van Regenmortel, M.H.V. et al. (1988). "Operational Aspects of Epitope Identification: Structural Features of Proteins Recognized by Antibodies," In <i>Vaccines: New Concepts and Developments</i> Kohler, H. et al. ed. Longman Scientific & Technical pp. 113-122.
205.	Villard, S. et al. (July 26, 2002). "Low Molecular Weight Peptides Restore the Procoagulant Activity of Factor VIII in the Presence of the Potent Inhibitor Antibody ESH8," <i>J. Biol. Chem.</i> 277(30):27232-27239.
206.	Vodyanik, M.A. et al. (2001). "Application of Cooperative Monoclonal Antibodies in the Enzyme Immunoassay for Detection of Human Tumor Necrosis Factor," <i>Uk Biokhim Zh.</i> 73(6):77-83. (Only Abstract in English.)
207.	Vodyanik, M.A. et al. (2001). "Functional Properties of Cooperative Monoclonal Antibodies Against Human Tumor Necrosis Factor," <i>Fiziol Zh.</i> 47(3):73-79. (Only Abstract in English.).
208.	Welschof, M. et al. (1999). "The Antigen Binding Domain of Non-Idiotype Human Anti-F(ab')2 Autoantibodies: Study of Their Interaction with IgG Hinge Region Epitopes," <i>Hum. Immunol.</i> 60:282-290.
209.	Westhoff, W.E. et al. (May 1996). "Detection of Epitopes on Follicle-Stimulating Hormone and FSH-Antiserum-Induced Suppression of Bioactivity of Follicle-Stimulating Hormone and Luteinizing Hormone," <i>J. Reprod. Immunol.</i> 30:133-149.
210.	Wilson, I.A. et al. (August 1985). "Identical Short Peptide Sequences in Unrelated Proteins Can Have Different Conformations: A Testing Ground for Theories of Immune Recognition," <i>Proc. Natl. Acad. Sci. USA</i> 82:5255-5259.
211.	Wobus, C.E. et al. (October 2000). "Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-Cell Interaction and Neutralization of AAV-2 Infection," <i>J. Virology</i> 74(19):9281-9293.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number 273402602309	Application Number 10/702,681
		Applicant	Deborah A. RATHJEN et al.
		Filing Date November 5, 2003	Group Art Unit 1644
		Mailing Date December 9, 2004	

212.	Wood, P.R. et al. (September 1988). "Production and Characterization of Monoclonal Antibodies Specific for <i>Mycobacterium bovis</i> ," <i>J. Gen. Microbiol.</i> 134(1):2599-2604.
213.	Woof, J.M. et al. (1986). "Localisation of the Monocyte-Binding Region on Human Immunoglobulin G," <i>Molec. Immunol.</i> 23(3):319-330.
214.	Yamazaki, S. et al. (1986). "Proposal of Standardized Methods and Reference For Assaying Recombinant Human Tumor Necrosis Factor," <i>Jap. J. Med. Sci. Biol.</i> 39:105-118.
215.	Yokota, S-I. et al. (1996). "A Polyreactive Human Anti-Lipid A Monoclonal Antibody Having Cross Reactivity to Polysaccharide Portions of <i>Pseudomonas aeruginosa</i> Lipopolysaccharides," <i>FEMS Immunology and Medical Microbiology</i> 14:31-38.
216.	Yone, K. et al. (August 18, 1995). "Epitopic Regions for Antibodies Against Tumor Necrosis Factor α ," <i>J. Biol. Chem.</i> 270(33):19509-19515.
217.	Zeder-Lutz, G. et al. (February 1993). "Monoclonal Antipeptide Antibodies: Affinity and Kinetic Rate Constants Measured for the Peptide and the Cognate Protein Using a Biosensor Technology," <i>Mol. Immunol.</i> 30(2):145-155.
218.	Zwick, M.B. et al. (June 2003). "A Novel Human Antibody Against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12," <i>Journal of Virology</i> 77(12):6965-6978.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	